| Title |
Mechanism and therapeutic effectiveness of nerve growth factor in osteoarthritis pain
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, August 2017
|
| DOI | 10.2147/tcrm.s139814 |
| Pubmed ID | |
| Authors |
Xiushuai Shang, Zhaofei Wang, Hairong Tao |
| Abstract |
Osteoarthritis (OA) is the most common form of articular joint arthritis and a cause of significant morbidity. In this review, we present the role of nerve growth factor (NGF) in pain generation, relationship between NGF and OA pain, and pathogenic factors (interleukin-1β, transforming growth factor-β1, mechanical loading, and adipokines) involved in OA development. Since NGF blocking is an efficient way to inhibit OA-associated pain, we summarize four categories of drugs that target NGF/tropomyosin receptor kinase A (TrkA) signaling. In addition, we discuss the future of NGF/TrkA antagonists and underline their potential for use in OA pain relief. A better understanding of the causes and treatment of OA will facilitate the development of more effective methods of OA pain management. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 73 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 18% |
| Other | 8 | 11% |
| Student > Ph. D. Student | 7 | 10% |
| Student > Master | 7 | 10% |
| Student > Bachelor | 4 | 5% |
| Other | 5 | 7% |
| Unknown | 29 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 23% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Biochemistry, Genetics and Molecular Biology | 5 | 7% |
| Agricultural and Biological Sciences | 4 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Other | 5 | 7% |
| Unknown | 33 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 August 2017.
All research outputs
#22,764,772
of 25,382,440 outputs
Outputs from Therapeutics and Clinical Risk Management
#1,204
of 1,323 outputs
Outputs of similar age
#287,031
of 327,503 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#26
of 29 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,503 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.